1C0 Stock Overview
A biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Celyad Oncology SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.21 |
| 52 Week High | €1.21 |
| 52 Week Low | €0.18 |
| Beta | 1.51 |
| 11 Month Change | 427.23% |
| 3 Month Change | 530.21% |
| 1 Year Change | 127.44% |
| 33 Year Change | -66.25% |
| 5 Year Change | -85.76% |
| Change since IPO | -96.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1C0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 417.1% | 0.7% | 1.1% |
| 1Y | 127.4% | -17.7% | 12.5% |
Return vs Industry: 1C0 exceeded the German Biotechs industry which returned -16.2% over the past year.
Return vs Market: 1C0 exceeded the German Market which returned 11.8% over the past year.
Price Volatility
| 1C0 volatility | |
|---|---|
| 1C0 Average Weekly Movement | 81.2% |
| Biotechs Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1C0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1C0's weekly volatility has increased from 43% to 81% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 18 | Matt Kane | www.celyad.com |
Celyad Oncology SA, a biopharmaceutical company, focuses on the research and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. The company is developing shRNA non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the TCR without the need for gene editing; multi-specific CAR T-cell platform that focuses on the NKG2D receptor; NKG2D-based CAR T-cell therapies; and B7-H6 targeting CAT T-cell therapies. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery/PerkinElmer for the use of its shRNA reagents to reduce expression of one or more defined targets.
Celyad Oncology SA Fundamentals Summary
| 1C0 fundamental statistics | |
|---|---|
| Market cap | €41.43m |
| Earnings (TTM) | -€7.75m |
| Revenue (TTM) | €72.00k |
575.4x
P/S Ratio-5.3x
P/E RatioIs 1C0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1C0 income statement (TTM) | |
|---|---|
| Revenue | €72.00k |
| Cost of Revenue | €34.00k |
| Gross Profit | €38.00k |
| Other Expenses | €7.79m |
| Earnings | -€7.75m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Apr 02, 2025
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 52.78% |
| Net Profit Margin | -10,766.67% |
| Debt/Equity Ratio | 0% |
How did 1C0 perform over the long term?
See historical performance and comparison